EG20218A - Process for preparing of substituted 3 aminoquinuclidines - Google Patents

Process for preparing of substituted 3 aminoquinuclidines

Info

Publication number
EG20218A
EG20218A EG27092A EG27092A EG20218A EG 20218 A EG20218 A EG 20218A EG 27092 A EG27092 A EG 27092A EG 27092 A EG27092 A EG 27092A EG 20218 A EG20218 A EG 20218A
Authority
EG
Egypt
Prior art keywords
compounds
aminoquinuclidines
substituted
preparing
disorders
Prior art date
Application number
EG27092A
Other languages
English (en)
Inventor
Pharmaceuticals Inc. Pfizer
Original Assignee
Pfizer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Pharma filed Critical Pfizer Pharma
Application granted granted Critical
Publication of EG20218A publication Critical patent/EG20218A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
EG27092A 1991-05-22 1992-05-21 Process for preparing of substituted 3 aminoquinuclidines EG20218A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14682691 1991-05-22

Publications (1)

Publication Number Publication Date
EG20218A true EG20218A (en) 1997-11-30

Family

ID=15416402

Family Applications (1)

Application Number Title Priority Date Filing Date
EG27092A EG20218A (en) 1991-05-22 1992-05-21 Process for preparing of substituted 3 aminoquinuclidines

Country Status (25)

Country Link
EP (1) EP0585328B1 (fi)
KR (1) KR100246065B1 (fi)
CN (1) CN1041827C (fi)
AT (1) ATE211743T1 (fi)
AU (1) AU658898B2 (fi)
BR (1) BR9206044A (fi)
CA (1) CA2109415C (fi)
CZ (1) CZ247993A3 (fi)
DE (2) DE9290057U1 (fi)
DK (1) DK0585328T3 (fi)
EG (1) EG20218A (fi)
ES (1) ES2168260T3 (fi)
FI (1) FI935134A (fi)
HU (1) HUT65771A (fi)
IE (1) IE921662A1 (fi)
IL (1) IL101960A (fi)
MX (1) MX9202449A (fi)
NO (1) NO305173B1 (fi)
NZ (2) NZ242880A (fi)
PL (4) PL171921B1 (fi)
PT (1) PT100514B (fi)
RU (1) RU2092486C1 (fi)
UA (1) UA26401C2 (fi)
WO (1) WO1992020676A1 (fi)
ZA (1) ZA923773B (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
DE69213451T2 (de) * 1991-06-20 1997-01-09 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
CA2141048C (en) * 1992-08-19 2003-03-18 Harry R. Howard Substituted benzylamino nitrogen containing non-aromatic heterocycles
JP2656699B2 (ja) * 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
JP2722279B2 (ja) * 1992-12-10 1998-03-04 ファイザー・インク． アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスｐのアンタゴニストとしての使用
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0708771B1 (en) * 1993-07-15 1998-10-07 Pfizer Inc. Benzyloxyquinuclidines as substance p antagonists
PT719253E (pt) * 1993-09-17 2004-07-30 Pfizer Piperidinas 3-amino-5-carboxi-substituidas e pirrolidinas 3-amino-4-carboxi-substituidas como antagonistas de taquicinina
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (fi) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists

Also Published As

Publication number Publication date
NZ242880A (en) 1995-10-26
CA2109415C (en) 1998-12-29
PL172069B1 (pl) 1997-07-31
CN1041827C (zh) 1999-01-27
BR9206044A (pt) 1995-03-01
NO934195L (no) 1993-11-19
DE9290057U1 (de) 1994-01-05
PL170513B1 (en) 1996-12-31
ES2168260T3 (es) 2002-06-16
PT100514A (pt) 1993-09-30
CN1068571A (zh) 1993-02-03
AU658898B2 (en) 1995-05-04
DE69232334D1 (de) 2002-02-14
PL170525B1 (en) 1996-12-31
KR100246065B1 (en) 2000-04-01
CA2109415A1 (en) 1992-11-23
WO1992020676A1 (en) 1992-11-26
NZ272941A (en) 1997-05-26
ATE211743T1 (de) 2002-01-15
PT100514B (pt) 1999-06-30
FI935134A0 (fi) 1993-11-19
UA26401C2 (uk) 1999-08-30
FI935134A (fi) 1993-11-19
EP0585328B1 (en) 2002-01-09
AU1927592A (en) 1992-12-30
DK0585328T3 (da) 2002-02-11
HU9303307D0 (en) 1994-03-28
DE69232334T2 (de) 2002-11-14
MX9202449A (es) 1993-03-01
ZA923773B (en) 1993-11-22
IL101960A0 (en) 1994-04-12
IE921662A1 (en) 1992-12-02
IL101960A (en) 1999-03-12
NO934195D0 (no) 1993-11-19
HUT65771A (en) 1994-07-28
EP0585328A1 (en) 1994-03-09
NO305173B1 (no) 1999-04-12
PL171921B1 (pl) 1997-06-30
RU2092486C1 (ru) 1997-10-10
CZ247993A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
MY107157A (en) Quinuclidine derivatives.
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
CA2102179A1 (en) Quinuclidine derivatives
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
HUT67028A (en) Indole derivatives, pharmeceutical compositions comprising them and process for their production
ES2006619A6 (es) Un metodo para preparar derivados de piridil-y pirimidil-piperazinas.
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
HUT71127A (en) 2,3,4,5-tetrahydro-1h-3-benzodiazepines and pharmaceutically acceptable acid additional salts thereof, pharmaceutical compositions containing them and process for their preparation
AU5608790A (en) New pyrrolidone derivatives, the process for their preparation and the pharmaceutical compositions containing them
PH24501A (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones
EP0522577A3 (en) Process for the preparation of pure 3,3',4,4'-tetraaminobiphenyl